Skip to content
Sandu Pharmaceuticals logo

Sandu Pharmaceuticals

524703 BSE
₹35.23

Close ·

P/E
19.25
View as Markdown
MCP
Close 4 Nov 2026 ₹35.23 −7.77 −18.1% 1Y
Start ₹43.00

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare

Price-based figures at the close · EPS basis: Standalone · TTM

ROCE
6.43%
Debt to Equity
0.00
EPS (TTM)
₹1.83
Book Value
₹36.48
Market Cap
—
P/E (TTM)
19.25
P/B
0.97
ROE
4.13%
Dividend Yield
2.78%
EBITDA
₹2.90 Cr
52W High
₹50.00
52W Low
₹30.00

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

57 Good

Data confidence 98/100

Category scores

Quality
66
Strong
Returns, margins, earnings quality 22% weight
Valuation
70
Strong
Cheap vs sector & own history 24% weight
Growth
43
Weak
Sales & profit trajectory 9% weight
Financial Health
60
Good
Solvency, leverage, coverage 9% weight
Momentum
40
Weak
Trend strength, vol-adjusted 12% weight
Ownership
50
Average
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

3
  • Company is almost debt free.
  • Stock is trading at 0.82 times its book value
  • Company's working capital requirements have reduced from 53.8 days to 42.0 days

Weaknesses

4
  • The company has delivered a poor sales growth of 3.54% over past five years.
  • Promoter holding is low: 37.8%
  • Company has a low return on equity of 3.85% over last 3 years.
  • Promoter holding has decreased over last 3 years: -5.12%

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallStrong Bearish1072
OscillatorsNeutral171
Moving AveragesStrong Bearish901

Key readings

RSI (14)
47.52
Neutral
MACD (12,26,9)
−0.33
Bullish
SMA (50)
36.52
Bearish
SMA (200)
37.88
Bearish

As of

Growth Rate

From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.

Revenue

Revenue growth by window
10Y+6.05%
5Y+3.54%
3Y+2.28%
1Y+4.08%
TTM+4.16%

Net profit

Net profit growth by window
10Y+12.61%
5Y+10.18%
3Y+5.21%
1Y+14.19%
TTM+9.94%

Operating cash flow

Operating cash flow growth by window
10YTurned positive
5Y−4.21%
3Y+203.00%
1Y+544.21%
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
10Y−3.15 pp
5Y+0.61 pp
3Y+0.48 pp
1Y+0.18 pp
TTM−0.03 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2017₹42.82 Cr
Mar 2018₹49.02 Cr
Mar 2019₹49.42 Cr
Mar 2020₹48.37 Cr
Mar 2021₹58.76 Cr
Mar 2022₹65.50 Cr
Mar 2023₹65.35 Cr
Mar 2024₹67.28 Cr
Mar 2025₹67.19 Cr
Mar 2026₹69.93 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2017−₹0.44 Cr
Mar 2018₹0.56 Cr
Mar 2019₹0.67 Cr
Mar 2020₹0.72 Cr
Mar 2021₹1.09 Cr
Mar 2022₹1.59 Cr
Mar 2023₹1.52 Cr
Mar 2024₹1.46 Cr
Mar 2025₹1.55 Cr
Mar 2026₹1.77 Cr

Quarterly Results

₹ Cr
524703 quarterly results, ₹ crore
Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
17.66
16.61
17.43
15.6
17.05
17.7
18.37
14.07
16.7
17.62
18.76
16.85
16.39
Expenses
17.31
15.79
16.92
15
16.64
16.78
17.37
13.62
16.17
16.76
17.72
16.28
15.86
Operating Profit
0.35
0.82
0.51
0.6
0.41
0.92
1
0.45
0.53
0.86
1.04
0.57
0.53
OPM %
1.98%
4.94%
2.93%
3.85%
2.4%
5.2%
5.44%
3.2%
3.17%
4.88%
5.54%
3.38%
3.23%
Other Income
0
0.09
0.03
0.31
0.04
0.03
0.02
0.07
0.02
0.05
0.01
0.37
0.02
Interest
0.02
0.01
0.02
0.01
0.02
0.03
0.03
0.03
0.03
0.03
0.03
0.03
0.03
Depreciation
0.12
0.13
0.14
0.19
0.16
0.17
0.19
0.15
0.18
0.17
0.17
0.16
0.16
PBT
0.21
0.77
0.38
0.71
0.27
0.75
0.8
0.34
0.34
0.71
0.85
0.75
0.36
Tax %
47.62%
27.27%
44.74%
16.9%
40.74%
32%
30%
2.94%
35.29%
26.76%
−14.12%
93.33%
36.11%
Net Profit
0.11
0.55
0.21
0.59
0.17
0.5
0.56
0.33
0.22
0.52
0.98
0.04
0.23
EPS (₹)
0.11
0.57
0.22
0.61
0.18
0.52
0.58
0.34
0.23
0.54
1.01
0.04
0.24

Profit & Loss

₹ Cr
524703 profit and loss, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
38.17
38.86
42.82
49.02
49.42
48.37
58.76
65.5
65.35
67.28
67.19
69.93
69.62
Expenses
35.74
35.97
40.97
46.55
47.33
46.92
56.6
62.62
62.86
64.98
64.43
66.93
66.62
Operating Profit
2.43
2.89
1.85
2.47
2.09
1.45
2.16
2.88
2.49
2.3
2.76
3
3
OPM %
6.37%
7.44%
4.32%
5.04%
4.23%
3%
3.68%
4.4%
3.81%
3.42%
4.11%
4.29%
4.31%
Other Income
0.14
0.12
0.56
0.12
0.57
0.45
0.19
0.08
0.33
0.42
0.17
0.44
0.45
Interest
1.37
1.64
1.49
1.23
1.01
0.43
0.11
0.11
0.08
0.06
0.1
0.11
0.12
Depreciation
0.57
0.69
0.87
0.6
0.64
0.55
0.56
0.53
0.52
0.58
0.67
0.68
0.66
PBT
0.63
0.68
0.05
0.76
1.01
0.92
1.68
2.32
2.22
2.08
2.16
2.65
2.67
Tax %
34.92%
22.06%
1000%
26.32%
34.65%
21.74%
35.12%
31.47%
31.08%
29.33%
28.24%
33.58%
—
Net Profit
0.41
0.54
−0.44
0.56
0.67
0.72
1.09
1.59
1.52
1.46
1.55
1.77
1.77
EPS (₹)
0.58
0.76
−0.62
0.79
0.95
1.02
1.38
1.8
1.57
1.51
1.6
1.83
1.83
Div. Payout %
0%
0%
0%
0%
0%
0%
36.33%
41.56%
0%
52.93%
49.86%
0%
—

Balance Sheet

₹ Cr
524703 balance sheet, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
7.08
7.08
7.08
7.08
7.08
7.08
7.92
8.81
9.66
9.66
9.66
9.66
Reserves
11.06
11.6
20.33
21
21.71
22.16
25.57
27.66
29.58
30.93
32.36
34.01
Borrowings
12.47
11.39
10.56
9.42
6.17
1.25
0.02
0
0
0
0.06
0.11
Other Liabilities
10.91
11.33
8.46
7.03
8.67
10.92
13.45
12.81
14.92
11.83
13.64
12.09
Total Liabilities
41.52
41.4
46.43
44.53
43.63
41.41
46.96
49.28
54.16
52.42
55.72
55.87
Fixed Assets
8.36
7.81
17.49
17.57
17.04
16.6
16.17
16
16.62
17.88
18.15
18.12
CWIP
0
0
0
0
0
0
0
0.48
0.42
0
0
0.06
Investments
0.7
0.73
0.99
1.12
1.13
0.82
0.24
9.11
9.66
10.43
11.22
12.3
Other Assets
32.46
32.86
27.95
25.84
25.46
23.99
30.55
23.69
27.46
24.11
26.35
25.39
Total Assets
41.52
41.4
46.43
44.53
43.63
41.41
46.96
49.28
54.16
52.42
55.72
55.87

Cash Flow

₹ Cr
524703 cash flow, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
4.75
−1.43
4.91
1.23
3.74
6.2
7.59
0.95
0.22
0.76
0.95
6.12
Investing
−0.18
0.05
−0.59
−0.62
−0.1
−0.37
−5.58
−5.47
0.53
−1.31
−0.18
−0.57
Financing
−1.9
−2.06
−2.33
−1.89
−4.26
−5.36
1.3
0.93
0.58
−0.72
−0.46
−0.94
Net Cash Flow
2.67
−3.44
1.99
−1.28
−0.62
0.48
3.31
−3.59
1.33
−1.27
0.31
4.6
Free Cash Flow
4.43
−1.58
4.3
0.6
3.63
6.09
7.46
0.11
−0.85
−0.67
0.01
5.4
CFO/OP
201
−42
195
63
194
437
373
64
37
55
55
229

Ratios

524703 financial ratios, annual
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
62.73
67.16
54.13
49.81
35.45
35.32
33.23
22.23
26.75
26.42
25.86
28.24
Inventory Days
210
207
152
147
191
209
118
115
168
137
161
121
Days Payable
103
101
58.22
38.75
60.93
83.69
70.57
69.63
98.3
46.96
51.05
51.68
Cash Conversion Cycle
169
173
148
158
166
160
80.52
67.67
96.15
117
136
97.61
Working Capital Days
68.47
105
60.69
30.16
40.1
72.06
39.51
42.41
52.33
56.75
62.8
41.96
ROCE %
6.8%
7.75%
4.26%
5.14%
5.58%
4.13%
5.59%
6.94%
6.08%
5.36%
5.47%
6.43%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Sandu Pharmaceuticals insights

66 extracted metrics across FY11–FY27.

Shareholding Pattern

As of Sep 2026

  • Promoters 37.79%
  • Public 37.08%
  • Others 25.12%
  • DIIs 0.02%

No promoter shares pledged as of 14 Oct 2026

Change vs previous quarter

Not shown for some quarters: Others. Not available separately for this quarter: the shareholding filing gives Public and Others as one figure, shown under Public, so Others is left blank rather than estimated.

Documents

Frequently Asked Questions about Sandu Pharmaceuticals

What does Sandu Pharmaceuticals Ltd do?
Incorporated in 1985, Sandu Pharmaceuticals Ltd is a manufacturer of Ayurvedic Medicines.
Where is Sandu Pharmaceuticals Ltd (SANDUPHQ) listed?
Sandu Pharmaceuticals Ltd trades under code 524703 on the BSE.
Which sector does Sandu Pharmaceuticals Ltd belong to?
Sandu Pharmaceuticals Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the PE ratio of Sandu Pharmaceuticals Ltd?
Sandu Pharmaceuticals Ltd trades at a PE ratio of 19.25 as of 4 Nov 2026, on earnings per share of ₹1.83, against a book value of ₹36.48 per share.
What is the 52-week high and low of Sandu Pharmaceuticals Ltd?
Over the last 52 weeks Sandu Pharmaceuticals Ltd has traded between ₹30 and ₹50 as of 4 Nov 2026.
Does Sandu Pharmaceuticals Ltd pay dividends?
Sandu Pharmaceuticals Ltd has a dividend yield of 2.78%.
What is the Return on Equity (ROE) of Sandu Pharmaceuticals Ltd?
Sandu Pharmaceuticals Ltd reported a return on equity of 4.13%. Its debt-to-equity ratio is 0.00.

Company Information

Incorporated in 1985, Sandu Pharmaceuticals Ltd is a manufacturer of Ayurvedic Medicines.

Website sandu.in
Face Value ₹10

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/524703.md for Sandu Pharmaceuticals Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month